Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeated Intraarterial Bevacizumab for Newly Diagnosed GBM
NCT01811498Phase 2Completed
- Sponsor
- Northwell Health
- Start
- Feb 2013
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in glioblastoma multiforme (GBM), sponsored by Northwell Health. Started Feb 2013; status: completed.
02
Drugs
bevacizumab
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT01811498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01811498.